drugset

drugset / Trial / NCT00108836

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

NCT00108836 ↗

Phase 2 Completed 400 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Timeline

Start: 2005-03
Primary completion: —
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emapunil	Small molecule	—	—

Indications